X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ALKEM LABORATORIES PLETHICO PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x -1.1 - - View Chart
P/BV x 0.0 7.1 0.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PLETHICO PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ALKEM LABORATORIES
Mar-16
PLETHICO PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3951,589 24.9%   
Low Rs311,232 2.5%   
Sales per share (Unadj.) Rs604.4417.5 144.8%  
Earnings per share (Unadj.) Rs32.556.3 57.7%  
Cash flow per share (Unadj.) Rs51.364.7 79.3%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs473.6292.9 161.7%  
Shares outstanding (eoy) m34.08119.57 28.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.4 10.4%   
Avg P/E ratio x6.625.1 26.2%  
P/CF ratio (eoy) x4.221.8 19.0%  
Price / Book Value ratio x0.54.8 9.3%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m7,262168,653 4.3%   
No. of employees `000NANA-   
Total wages/salary Rs m1,5969,171 17.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,59849,915 41.3%  
Other income Rs m3861,645 23.5%   
Total revenues Rs m20,98451,561 40.7%   
Gross profit Rs m2,8188,482 33.2%  
Depreciation Rs m6421,006 63.9%   
Interest Rs m1,593671 237.6%   
Profit before tax Rs m9698,451 11.5%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,606 -8.6%   
Profit after tax Rs m1,1076,731 16.4%  
Gross profit margin %13.717.0 80.5%  
Effective tax rate %-14.319.0 -75.2%   
Net profit margin %5.413.5 39.8%  
BALANCE SHEET DATA
Current assets Rs m18,87727,062 69.8%   
Current liabilities Rs m11,89615,324 77.6%   
Net working cap to sales %33.923.5 144.1%  
Current ratio x1.61.8 89.9%  
Inventory Days Days3667 54.0%  
Debtors Days Days19841 479.2%  
Net fixed assets Rs m9,86112,610 78.2%   
Share capital Rs m341239 142.5%   
"Free" reserves Rs m12,33134,490 35.8%   
Net worth Rs m16,13935,027 46.1%   
Long term debt Rs m4,7061,212 388.4%   
Total assets Rs m33,14654,387 60.9%  
Interest coverage x1.613.6 11.8%   
Debt to equity ratio x0.30 843.0%  
Sales to assets ratio x0.60.9 67.7%   
Return on assets %8.113.6 59.9%  
Return on equity %6.919.2 35.7%  
Return on capital %12.324.9 49.4%  
Exports to sales %21.412.9 165.1%   
Imports to sales %15.23.1 493.4%   
Exports (fob) Rs m4,4026,461 68.1%   
Imports (cif) Rs m3,1361,540 203.6%   
Fx inflow Rs m4,4026,563 67.1%   
Fx outflow Rs m3,1843,012 105.7%   
Net fx Rs m1,2193,552 34.3%   
CASH FLOW
From Operations Rs m2,4377,259 33.6%  
From Investments Rs m-6,2651,864 -336.1%  
From Financial Activity Rs m2,490-9,273 -26.9%  
Net Cashflow Rs m-1,337-150 891.4%  

Share Holding

Indian Promoters % 82.7 66.9 123.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 33.1 13.0%  
FIIs % 5.5 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 0.0 -  
Shareholders   10,665 68,381 15.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS